Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Italy Fines Apple €98.6 Million Over App Store Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
ST. LOUIS PARK, Minn., Jan. 23, 2017 -- NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of J. Alex Martin, who currently serves as a director on the Company’s Board, as Board Chairman, effective immediately. Michael Fulton, M.D., the Company’s current Board Chairman, will remain as an integral member of the Board of Directors.
“Alex has over 40 years of experience in the healthcare and medical device industries, and I am delighted that NeoChord can further benefit from his leadership in his new role as Board Chairman,” said David Chung, President and Chief Executive Officer of NeoChord. “His proven executive experience and track record in high growth organizations will be invaluable to NeoChord as we continue to advance our strategic objectives. In prior roles, Alex has been instrumental in driving business development activities and broad corporate growth. I also would like to thank Dr. Fulton for his many contributions and direction as Board Chairman, including his role as Interim CEO, while leading the CEO search committee in 2014. We look forward to his future contributions as a director and greatly appreciate his continued dedication and commitment to NeoChord.”
“I am pleased to continue working alongside the company’s outstanding management team and my fellow board members,” said Alex Martin. “I deeply believe in NeoChord’s mission and am very encouraged that their new off-pump approach provides a significant solution for a disease that currently can only be addressed with more invasive bypass pump surgery.”
Mr. Martin has significant corporate executive of the healthcare and medical device industries experience. He previously served as the President and CEO of Coherex Medical, where he led the company to a successful exit with Biosense Webster, a Johnson and Johnson company, in November 2015. Prior to Coherex, Mr. Martin was the President and CEO of WorldHeart Corporation, where he led the company to a successful exit with HeartWare in August 2012. Previously, Mr. Martin has held senior leadership roles with Edwards Lifesciences, Cordis Corporation, a Johnson & Johnson Company, and SonaMed Corporation. Mr. Martin holds a bachelor’s degree from the University of Kentucky.
About NeoChord, Inc.
Founded in 2007 and based in St. Louis Park, Minnesota, NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for DMR. NeoChord’s DS1000 system received CE market clearance in December 2012. NeoChord received IDE approval from the FDA for the US pivotal trial in May 2016. For more information, please visit the Company's website at www.neochord.com.
The NeoChord DS1000 System is CE marked and approved for sale in Europe.
CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.
NeoChord, DS1000, ReChord, and the stylized logo are trademarks of NeoChord Corporation.
Contact: Bruce Van Deman NeoChord, Inc. (952) 698-7812 or (949) 413-1301 [email protected]
